LPCNHealthcare · BiotechnologyThe 2 Wall Street analysts covering Lipocine, Inc. hold a median 12-month price target of $5 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 6 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lipocine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LPCN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +127.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | $4.00 |
| 6 Apr 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 6 Apr 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 21 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 May 2025 | HC Wainwright & Co. | Assumes | Buy | $8.00 |
| 24 Sept 2024 | Alliance Global Partners | Initiates | Buy | $10 |
| 27 July 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 26 Aug 2021 | HC Wainwright & Co. | Maintains | Buy | $2.50 → $3.50 |
| 24 June 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 27 May 2021 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $2.50 |
| 10 Dec 2020 | Ladenburg Thalmann | Upgrade | Buy | — |
| 27 May 2020 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $3.00 |
| 29 Mar 2018 | Seaport Global | Initiates | Buy | — |
| 27 Feb 2018 | Empire Asset Management | Upgrade | Buy | — |
| 11 Jan 2018 | Canaccord Genuity | Downgrade | Hold | — |
| 7 Oct 2016 | H.C. Wainwright | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LPCN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Lipocine, Inc. returned −31.7% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 14% of US stocks
Cheaper than 78% of US stocks
Cheaper than 59% of US stocks
Higher than 4% of US stocks
Higher than 7% of US stocks
Higher than 1% of US stocks
Higher than 5% of US stocks
Higher than 1% of US stocks
Higher than 19% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lipocine, Inc. has a market value of $17.3M and an enterprise value of −$5.7M.
Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 69.5% year on year.
Net income over the same four quarters: −$11.9M, a −755.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$11.2M.
Trailing P/E: −1.2×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lipocine, Inc. employs 14 people — $112K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lipocine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Health Canada approved TLANDO (testosterone undecanoate) capsules for Lipocine and its licensing partner, Verity Pharmaceuticals.
Why it matters — The approval marks progress for Lipocine’s oral testosterone option in Canada.
Lipocine announced that Health Canada approved TLANDO® testosterone undecanoate capsules for testosterone replacement therapy in adult males with male hypogonadism. Its licensing partner Verity Pharma plans to launch and commercialize the product in Canada by the end of 2026.
Why it matters — The approval and planned Canadian launch are developments involving a Lipocine product licensed to its commercial partner.
Lipocine (LPCN) was upgraded by Zacks Investment Research to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The rating change could potentially drive the stock higher in the near term.
Why it matters — A Zacks upgrade to a Buy rating signals increased positive sentiment among analysts about Lipocine's earnings outlook, which stock watchers would view as a favorable development.
Lipocine announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression. The study plans to enroll approximately 120 participants with severe PPD, with first participant dosing expected in early Q4 2026, and is informed by encouraging exploratory efficacy findings and a favorable safety profile from a prior Phase 3 trial.
Why it matters — This marks progress in advancing LPCN 1154 toward potential approval for postpartum depression, a key pipeline candidate for the company.
Lipocine announced that its management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference on September 10, 2026. The company is focused on developing novel oral therapeutics.
Why it matters — The presentation offers LPCN watchers an opportunity for the company to engage with the investment community at a major industry conference.
The 2 Wall Street analysts covering Lipocine, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Lipocine, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lipocine, Inc. 34 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Lipocine, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks Lipocine, Inc. 34 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lipocine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LPCN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
Lipocine, Inc. returned -31.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate.
The most recent item we track (Benzinga, 7 Oct 2026): "Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada". Health Canada approved TLANDO (testosterone undecanoate) capsules for Lipocine and its licensing partner, Verity Pharmaceuticals.
Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate. The company’s current portfolio includes TLANDO, an oral testosterone replacement therapy for men with low testosterone, and LPCN 1154 (BRLIZIO™), an oral neurosteroid under development for postpartum depression. Lipocine also advances additional product candidates across hormone-related, liver, and women’s health areas, using its proprietary delivery technology platform to support convenient oral dosing and differentiated therapeutic profiles. Based in Salt Lake City, Utah, Lipocine operates in the specialty pharmaceuticals and clinical-stage biotechnology markets, with its work centered on translating complex drug molecules into patient-friendly oral treatments.
CEO Dr. Mahesh V. Patel Ph.D. · 14 employees · United States · https://www.lipocine.com
